RCM
FUSN

RA Capital Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

RA Capital Management’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-659,992
Closed -$2.49M – 60
2023
Q1 		$2.49M Hold
659,992
– – 0.06% 57
2022
Q4 		$2.08M Hold
659,992
– – 0.04% 65
2022
Q3 		$1.99M Buy
+659,992
New +$1.65M 0.04% 76

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

RA Capital Management's FUSN Position: Q2 2023 in Review

RA Capital Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2023, closing a stake of 659,992 shares — an estimated $2.49M sold.

RA Capital Management first reported a position in FUSN in Q3 2022 and held it in 3 quarters. The position peaked at $2.49M in Q1 2023. 41 funds tracked by Wall St. Rank hold FUSN as of Q2 2023.

  • RA Capital Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2023 after selling out during the quarter.
  • RA Capital Management sold 659,992 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2023, an estimated $2.49M.
  • RA Capital Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q3 2022 and held it in 3 quarters.
  • RA Capital Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.49M in Q1 2023.
  • 41 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2023.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.